This image is not available for purchase in your country.

Treatment of Acute Lymphoblastic Leukaemia with Blinatumobab

Treatment of Acute Lymphoblastic Leukaemia with Blinatumobab

C044/0394

Rights Managed

28.8 MB (4.4 MB compressed)

2811 x 3580 pixels

23.9 x 30.2 cm ⏐ 9.4 x 11.9 in (300dpi)

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

DNA ILLUSTRATIONS / SCIENCE SOURCE / SCIENCE PHOTO LIBRARY DNA ILLUSTRATIONS / SCIENCE SOURCE / SCIENCE PHOTO LIBRARY

Caption

There are limited treatment options of a rare form of adult leukaemia (Acute Lymphoblastic Leukaemia, ALL) for patients with relapsed or refractory Philadelphia chromosome negative (ph-) ALL. Blinatumomab is first in a class of immunotherapy agents called a bispecific T cell-engager (BiTE) antibody. The two antigens targeted by the bispecific design is CD3 which is found on cytotoxic T cell, and CD19 which is found on B lymphocytes throughout their development.

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Calculate price
  • Add to board